Abstract
The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8–9 months and a 3-year overall survival (OS) rate less than 15% [1,2].
A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4].
Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5].
To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].
Keywords: Melanoma, immunotherapy, B-RAF inibithors, chemotherapy.
Anti-Cancer Agents in Medicinal Chemistry
Title:Multidisciplinary Approach to Patient with Malignant Melanoma
Volume: 13 Issue: 6
Author(s): Giuseppina Della Vittoria Scarpati, Celeste Fusciello, Francesco Sabbatino, Soldano Ferrone, Francesco Caponigro, Francesco Perri, Chiara Carlomagno and Stefano Pepe
Affiliation:
Keywords: Melanoma, immunotherapy, B-RAF inibithors, chemotherapy.
Abstract: The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8–9 months and a 3-year overall survival (OS) rate less than 15% [1,2].
A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4].
Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5].
To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].
Export Options
About this article
Cite this article as:
Scarpati Della Vittoria Giuseppina, Fusciello Celeste, Sabbatino Francesco, Ferrone Soldano, Caponigro Francesco, Perri Francesco, Carlomagno Chiara and Pepe Stefano, Multidisciplinary Approach to Patient with Malignant Melanoma, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990079
DOI https://dx.doi.org/10.2174/18715206113139990079 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
Current Cancer Drug Targets Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations
Current Pharmacogenomics Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database
Current Reviews in Clinical and Experimental Pharmacology NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Towards the Targeted Therapy of Melanoma
Mini-Reviews in Medicinal Chemistry Cannabinoids in Energy Balance and Prospectives in the Therapy of Obesity
Current Medicinal Chemistry - Central Nervous System Agents Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Glycosidated Phospholipids – a Promising Group of Anti-Tumour Lipids
Anti-Cancer Agents in Medicinal Chemistry Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design